psoriasis

News

BMS' deucravacitinib psoriasis pill could launch next year a...

Bristol-Myers Squibb has phase 3 data from its deucravacitinib psoriasis pill, showing it outperformed Amgen’s rival Otezla in patients with moderate to severe disease.

News

Sanofi licences in potential oral IL-17 drug from UK's C4X D...

Sanofi has licensed a potential inflammatory diseases drug from Manchester University spin-off C4X Discovery Holdings in a deal worth up to €414 million ($492 million).

News

four smiling fingers that are very happy to be friends, family concept

Almirall, Happify partner on digital tool for psoriasis ment...

It’s well recognised that people with psoriasis can develop depression or anxiety, particularly in moderate or severe cases where a sizeable part of the body can have skin lesions.

Partner Content